MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Clinical studies roundup: Survival rates improving for some heart attacks

Clinical studies roundup: Survival rates improving for some heart attacks

By

Clinical trials roundup

Here’s a roundup of recent clinical study and trial news:

  • Survival rates improving for some heart attacks
    Some heart attack rates are declining as survival rates improve, according to a news study done at the University of Mass. Medical School. “The results of this study demonstrate recent decreases in the magnitude of STEMI (ST-segment elevation acute myocardial infarction), slight increases in the incidence rates of NSTEMI (non-ST-segment acute myocardial infarction), and decreases in long-term mortality in patients with STEMI and NSTEMI. Our findings suggest that acute myocardial infarction prevention and treatment efforts have resulted in favorable decreases in the frequency of STEMI and death rates from the major types of acute myocardial infarction,” UMass Medical School Division of Cardiovascular Medicine Departments of Quantitative Health Sciences and Medicine lead investigator Dr. David McManus wrote in the study’s conclusion.
    Read more

  • New England Journal of Medicine publishes initial data on study examining impact of personal genomics
    Navigenics, a leading personal genomics company, announced that The New England Journal of Medicine published findings from the Scripps Genomic Health Initiative, a research study sponsored by Scripps Translational Science Institute to assess the behavioral impact of personal genetic testing. The Scripps Genomic Health Initiative provided study participants who were age 18 and older with personalized genetic risk assessments for more than 20 health conditions that may be changed by health screening and lifestyle, including diabetes, heart attack and some forms of cancer. The study was launched in 2008 and will assess changes in participants’ behaviors over a 20-year period. As a co-sponsor of the study, Navigenics provided the genetic testing used in the study. Initial results from the Scripps Genomic Health Initiative were published Jan. 12, 2011 in an article on NEJM’s website.
    Read more

  • Targeted gold nanoparticles and noninvasive radio fields attacking one of the deadliest and least curable types of cancer: pancreatic carcinoma
    Kanzius Cancer Research Foundation announces research conducted in the Kanzius/Curley Lab at The University of Texas M.D. Anderson Cancer Center has been published in the December 2010 issue of the American Association of Cancer Research’s Clinical Cancer Research journal. The manuscript illustrates how Drs. Steven Curley and Evan Glazer’s studies prove that radiofrequency fields can treat pancreatic tumors, which today, kill more than 95 percent of diagnosed patients. Studies found that noninvasive radiofrequency ields were effective in controlling relatively large malignant pancreatic tumors. Additionally, this process took place without any injury to surrounding tissue or changes in non-human subject behavior.
    Read more

  • Biosense Webster completes first atrial fibrillation ablation cases in the E.U. using the Thermocool Smarttouch contact force sensing catheter
    Biosense Webster Inc., a Johnson & Johnson (NYSE:JNJ) company, and a global company in the diagnosis and treatment of cardiac arrhythmias, announced the successful completion of the first clinical cases with the new THERMOCOOL(R) SMARTTOUCH(TM) Contact Force Sensing Catheter in the European Union, following recent CE-marking of the product.
    Read more

  • Mount Sinai Medical Center of Miami Beach study reports minimally invasive valve surgery superior to standard breastbone-splitting surgery in elderly patients
    The Annals of Thoracic Surgery published in its Jan. 2011 issue a study conducted at Mount Sinai Medical Center of Miami Beach reporting the outcomes of minimally invasive valve surgery versus traditional median sternotomy in patients 75 years of age or older. Minimally invasive valve surgery at Mount Sinai is performed through a small, 2-inch incision on the right side of the chest, and this was compared with the same kind of valve surgery done through a breastbone splitting approach. The investigators hypothesized that in elderly patients, a smaller, less traumatic surgery would lead to better results. Minimally invasive valve surgery in elderly patients increased survival, reduced postoperative complications, and shortened length of hospital stay when compared with traditional median sternotomy surgery.
    Read more

  • CIRC trial concludes
    ZOLL Medical Corp. (NSDQ:ZOLL), a manufacturer of medical devices and related software solutions, announced the successful conclusion of the ZOLL-sponsored CIRC (Circulation Improving Resuscitation Care) trial. The trial’s Data Safety Monitoring Board (DSMB) closed enrollment when an analysis of the data showed the load-distributing band (AutoPulse® Non-invasive Cardiac Support Pump) to be equivalent to manual chest compressions. The CIRC trial compares the rates of survival to hospital discharge from out-of-hospital cardiac arrest of patients treated with the load-distributing band device to those receiving manual CPR. The trial commenced in 2007 and enrolled approximately 4,000 patients. The trial was governed by an independent DSMB that reviewed interim outcome and safety data on seven separate occasions.
    Read more

  • Clinical study using Revolutions Medical’s MRI software tools receives IRB approval
    Revolutions Medical Corp. (OTC:RMCP) is happy to report that it has received notice that Investigational Review Board (IRB) approval has been granted this month to the Philadelphia College of Osteopathic Medicine for the research project application titled ‘Characterization of Intracranial Hemorrhages by Color MRI Automatic Segmentation,’ by Dr. H. Keith Brown and his collaborators. With this new approval, the team of research scientists and clinicians will now begin collecting and analyzing diagnostic images from cases of intracranial hemorrhages using RevColor™, Rev3D™, and RevDisplay™ MRI software.
    Read more

  • WorldHeart announces Levacor VAD implant at Tampa General Hospital; Enrollment in Bridge-to-Transplant study continues to be slow as WorldHeart makes refinements to Levacor VAD
    World Heart Corporation (NSDQ:WHRT), a developer of mechanical circulatory systems, announced that Tampa General Hospital in Tampa, Florida has successfully implanted its first Levacor Ventricular Assist Device (VAD). Tampa General is the sixth implanting site nationwide in the Levacor VAD Bridge-to-Transplant (BTT) Study. This is the 15th implant with the Levacor VAD since the inception of the BTT Study.
    Read more

  • St. Francis Hospital to be part of major nationwide study using a catheter-based aortic valve replacement
    Dr. Newell Robinson, Chairman of the Department of Cardiothoracic & Vascular Surgery; Dr. George Petrossian, Director of Interventional Cardiovascular Procedures; Dr. Andrew Berke, interventional cardiologist; and Dr. Roberto Colangelo, cardiothoracic surgeon at St. Francis Hospital, The Heart Center® are part of the medical team that is testing a device that may offer new hope for patients with symptomatic, severe aortic stenosis.
    Read more

In case you missed it

RSS From Medical Design & Outsourcing

  • How Stryker includes users for product design in the digital age
    Medical device developers and manufacturers like Stryker (NYSE:SYK) are changing how they approach design as digital technology becomes more crucial. Four Stryker executives shared how the Kalamazoo, Michigan–based orthopedic device giant is thinking differently about medical product development and how health care providers and patients will ultimately use them. The DeviceTalks Boston panel of Stryker… […]
  • DermaSensor wins MedTech Innovator Mid-Stage Companies Pitch Event
    DermaSensor Inc. — the creator of a handheld, point-and-click device to quickly assess skin lesions for cancer risk — is the winner of the MedTech Innovator Mid-Stage Companies Pitch Event.  The Miami-based mid-stage company beat out 1,000 applicants, more than 20 of which competed on-site May 10–11, 2022 at DeviceTalks Boston. DermaSensor walked away with… […]
  • Steris rises on Street-beating Q4, sets fiscal 2023 guidance
    Steris (NYSE:STE) shares ticked up today on fourth-quarter financial results that came in just ahead of the consensus forecast. The infection prevention technology company — headquartered in Dublin, Ireland, and run operationally out of Mentor, Ohio — posted profits of $52.3 million, or 52¢ per share, on sales of $1.2 billion for the three months… […]
  • Lucira Health asks FDA for EUA on molecular at-home COVID/flu test
    Lucira Health (Nasdaq: LHDX) today said it has asked the FDA for an emergency use authorization (EUA) for its combination COVID-19 and flu test. Emeryville, California–based Lucira said the at-home test would be available with a prescription to test for SARS-CoV-2, Influenza A and Influenza B. The Nucleic Acid Amplification Test (NAAT) platform has a… […]
  • Device commercialization platform AcuityMD raises $31M Series A to fund R&D engineer hiring
    AcuityMD said today it has raised $31 million in Series A funding for its medical device commercialization platform. “With our new funding, we plan to double down on R&D by growing our engineering team from 15 to over 40 over the next year,” AcuityMD co-founder and CEO Michael Monovoukas said in a blog post. “We’ll… […]
  • Rockley Photonics announces $81.5M private placement
    Rockley Photonics (NYSE:RKLY) announced today that it entered into agreements for an $81.5 million private placement. Participating investors agreed to purchase $81.5 million in convertible senior secured notes (due 2026) and warrants to purchase 26.5 million Rockley ordinary shares at an exercise price of $5 per share, subject to certain anti-dilution adjustments. Warrants purchased in… […]
  • Stryker leaders talk medtech trends at DeviceTalks Boston: ‘If you’re slow, you’re going to lose’
    The first day of DeviceTalks Boston closed with a panel of Stryker (NYSE:SYK) executives discussing new tools, technologies and strategies in medtech. Digital VP Tracy Robertson, Digital, Robotics, and Enabling Technologies President Robert Cohen and Surgical Technologies VP of Digital Innovation Siddarth Satish offered their thoughts on industry trends in healthcare and at the Kalamazoo,… […]
  • Medtronic’s VC leader discusses risk, returns, strategy and an ‘ugly truth’
    A panel of medtech investors convened today for DeviceTalks Boston included David Neustaedter, VP of venture capital at Medtronic (NYSE: MDT). He’s spent 14 years in the role, including as director of venture capital at Covidien before Medtronic acquired the company. (Read more in his DeviceTalks speaker bio.) Medtronic has more than $500 million in… […]
  • Here’s where Harvard’s engineering dean sees medtech research going
    Surgical robotics, artificial intelligence, and combatting climate change are but some of the priorities that have Harvard’s engineering school dean excited. Speaking today at DeviceTalks Boston, Frank J. Doyle III described the Harvard John A. Paulson School of Engineering and Applied Sciences as a “well-kept secret” historically. But Harvard engineering is staking out a strong position when it… […]
  • gBETA Medtech accelerator picks its next startups
    The gBETA Medtech virtual accelerator today named the five startups that will participate in the spring program leading up to the June 21 showcase day. The five startups for the spring 2022 cohort are: Mother of Fact: This mobile app for moms with babies offers nutrition tracking, preventative monitoring and daily coaching from licensed dietitians… […]
  • FDA warns of potential toxic risk from Fresenius hemodialysis machines
    The FDA is evaluating the risk of exposure to toxic chemicals from silicone tubing used in Fresenius Medical Care (NYSE: FMS) hemodialysis machines. The investigation concerns three models of Fresenius hemodialysis machines: the 2008T, 2008K2, and 2008K. The chemicals — non-dioxin-like (NDL) polychlorinated biphenyl acids (PCBAs) and NDL polychlorinated biphenyls (PCBs) — are in the… […]

Leave a Reply